New York, Feb 21, 2026, 10:10 EST — The market has closed.
- GE HealthCare finished Friday’s session at $84.23, climbing 1.47% and notching a win for the fifth day in a row.
- This week, the company reported it had received FDA 510(k) clearances for two MRI systems, along with an AI-powered workflow platform.
- Management will address investors at events scheduled for Feb. 26 and March 10. Traders are waiting to hear any new insights on orders and margins.
GE HealthCare Technologies Inc wrapped up Friday up at $84.23, adding a fifth straight win as U.S. stocks ended the week positive.
The stock’s trajectory is in focus going into next week. GE HealthCare has been rolling out fresh scanner upgrades, and investors are tracking whether hospitals keep up spending on pricey imaging systems. Imaging is GE HealthCare’s largest segment, and shifts in its product cycle often surface in order chatter ahead of making a mark on earnings.
GE HealthCare announced Thursday it has scored U.S. FDA 510(k) clearance for a pair of MRI machines—Signa Sprint with Freelium, and Signa Bolt—plus its AI-powered workflow system Signa One. The 510(k) process lets companies bring devices to market by showing they’re substantially equivalent to existing cleared products.
Kelly Londy, president and CEO of MR for the company, described the clearances as moving closer to “greater efficiency without compromising diagnostic precision,” according to GE HealthCare’s release, as reported by Radiology Business.
One of the newly cleared devices is a 1.5-tesla system that requires less than 1% of the helium used by standard magnets. Another is a 3-tesla model, which targets lower peak power needs, according to industry reports referencing the company. GE HealthCare said it plans to seek the CE Mark in Europe for all three systems before 2026 wraps up.
The stock wrapped up Friday’s session close to the high end of a broad intraday swing, with more than 5 million shares changing hands, according to data. Investors digested a U.S. Supreme Court tariffs ruling as the broader market advanced.
GE HealthCare says it’s counting on “healthy capital investment trends” and appetite for new offerings. Earlier this month, the company projected 2026 profit ahead of what Wall Street had penciled in. https://www.reuters.com/business/healthcare-pharmaceuticals/ge-healthcare-forecasts-2026-profit-above-estimates-strong-demand-medical-2026-02-04/
Even with FDA clearance in hand, orders aren’t guaranteed. Hospitals face tightening budgets and rivals are ramping up their own MRI upgrades, so the real test is whether buyers pull the trigger. Any slowdown in adoption, or holdups abroad, could wear thin the market’s nerves after the stock’s recent gains.
Timing on the deal remains a factor. GE HealthCare is aiming to wrap up its $2.3 billion acquisition of imaging software maker Intelerad sometime in the first half of 2026, assuming regulators give the go-ahead. Back in November, BTIG’s Ryan Zimmerman noted that pulling the two together could speed up imaging AI uptake.
The next real mover for GE HealthCare? That’s the company’s own upcoming appearances. Management plans to present at Citi’s Unplugged MedTech and Life Sciences Access Day on Feb. 26, then heads to the Barclays Global Healthcare Conference on March 10.
Related articles: Stock Market
